

Press release

## FINMA has allowed Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd, Xiang Xu, Kun Shen and Mengke Cai to exercise their voting rights during the pending appeal period against the Swiss Takeover Board (TOB) decision to suspend said rights

**Tel Aviv / Zurich, 09 October 2018 –** SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("SHL"), a leading provider and developer of advanced personal telemedicine solutions, announced today that on 8 October 2018 the Swiss Financial Market Supervisory Authority FINMA has resolved to re-establish the so called suspensive effect of the Swiss Takeover Board (TOB) decision (decision 672/04) to suspend the voting rights of the mandatory bidders - Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd., Xiang Xu, Kun Shen, and Mengke Cai - meaning that the voting rights of the mandatory bidders shall not be suspended while the appeal against said TOB decision is pending.

## For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

## About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit the web site at <a href="http://www.shl-telemedicine.com">www.shl-telemedicine.com</a>.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.